Overview
Study information
| Network: | CAVD |
| Grant Affiliation: | Ho: Ibalizumab for HIV Prevention |
| Strategy: | Prophylactic neutralizing Ab |
| Study Type: | Antibody Screening |
| Species: | Non-Organism Study |
| Stage: | Assays Completed |
| Study Start Date: | 2010-12-21 |
| Study Made Public: | 2016-02-16 |
Title
Engineering Bispecific Antibodies to Enhance HIV-Neutralizing Activity
Description
CAVD 261 is an immunogenicity study to assess the potency and breadth of the humanized monoclonal antibody, Ibalizumab, against a diverse virus panel.
Sign in to see full information about this study and to download study data.
Products
No Products used in studyIntegrated data
No integrated data is available for this study.
Non-integrated data
No non-integrated data is available for this study.